BRPI0402382A - Formas polimórficas de rifaximina, processos para a produção das mesmas e uso das mesmas em preparações medicinais - Google Patents

Formas polimórficas de rifaximina, processos para a produção das mesmas e uso das mesmas em preparações medicinais

Info

Publication number
BRPI0402382A
BRPI0402382A BR0402382-0A BRPI0402382A BRPI0402382A BR PI0402382 A BRPI0402382 A BR PI0402382A BR PI0402382 A BRPI0402382 A BR PI0402382A BR PI0402382 A BRPI0402382 A BR PI0402382A
Authority
BR
Brazil
Prior art keywords
rifaximin
production
forms
processes
polymorphic forms
Prior art date
Application number
BR0402382-0A
Other languages
English (en)
Inventor
Giuseppe C Viscomi
Manuela Campana
Dario Braga
Donatella Confortini
Vincenzo Cannata
Denis Severini
Paolo Righi
Goffredo Rosini
Original Assignee
Alfa Wassermann Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33187382&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0402382(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Alfa Wassermann Spa filed Critical Alfa Wassermann Spa
Publication of BRPI0402382A publication Critical patent/BRPI0402382A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • H—ELECTRICITY
    • H05—ELECTRIC TECHNIQUES NOT OTHERWISE PROVIDED FOR
    • H05B—ELECTRIC HEATING; ELECTRIC LIGHT SOURCES NOT OTHERWISE PROVIDED FOR; CIRCUIT ARRANGEMENTS FOR ELECTRIC LIGHT SOURCES, IN GENERAL
    • H05B6/00—Heating by electric, magnetic or electromagnetic fields
    • H05B6/02—Induction heating
    • H05B6/10—Induction heating apparatus, other than furnaces, for specific applications
    • H05B6/12—Cooking devices
    • H05B6/1209—Cooking devices induction cooking plates or the like and devices to be used in combination with them
    • H05B6/1236—Cooking devices induction cooking plates or the like and devices to be used in combination with them adapted to induce current in a coil to supply power to a device and electrical heating devices powered in this way
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • H—ELECTRICITY
    • H05—ELECTRIC TECHNIQUES NOT OTHERWISE PROVIDED FOR
    • H05B—ELECTRIC HEATING; ELECTRIC LIGHT SOURCES NOT OTHERWISE PROVIDED FOR; CIRCUIT ARRANGEMENTS FOR ELECTRIC LIGHT SOURCES, IN GENERAL
    • H05B6/00—Heating by electric, magnetic or electromagnetic fields
    • H05B6/02—Induction heating
    • H05B6/10—Induction heating apparatus, other than furnaces, for specific applications
    • H05B6/12—Cooking devices
    • H05B6/1209—Cooking devices induction cooking plates or the like and devices to be used in combination with them
    • H05B6/1245—Cooking devices induction cooking plates or the like and devices to be used in combination with them with special coil arrangements
    • H05B6/1263—Cooking devices induction cooking plates or the like and devices to be used in combination with them with special coil arrangements using coil cooling arrangements

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Physics & Mathematics (AREA)
  • Electromagnetism (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)

Abstract

"FORMAS POLIMóRFICAS DE RIFAXIMINA, PROCESSOS PARA A PRODUçãO DAS MESMAS E USO DAS MESMAS EM PREPARAçõES MEDICINAIS". A presente invenção refere-se a formas polimórficas cristalinas do antibiótico rifaximina (INN) denominadas rifaximina <244> e rifaximina <225> e uma forma fracamente cristalina denominada rifaximina <sym>. Estas formas são úteis na produção de preparações medicinais para uso oral e tópico e podem ser obtidas por meio de um processo de cristalização realizado por dissolução a quente da rifaximina bruta em álcool etílico e provocando-se a cristalização do produto pela adição de água a uma temperatura predeterminada e durante um período de tempo determinado. A cristalização é seguida de secagem realizada sob condições controladas até que seja conseguido um teor de água específico no produto final.
BR0402382-0A 2003-11-07 2004-03-19 Formas polimórficas de rifaximina, processos para a produção das mesmas e uso das mesmas em preparações medicinais BRPI0402382A (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT002144A ITMI20032144A1 (it) 2003-11-07 2003-11-07 Forme polimorfe di rifaximina, processi per ottenerle e

Publications (1)

Publication Number Publication Date
BRPI0402382A true BRPI0402382A (pt) 2005-06-28

Family

ID=33187382

Family Applications (2)

Application Number Title Priority Date Filing Date
BR0402382-0A BRPI0402382A (pt) 2003-11-07 2004-03-19 Formas polimórficas de rifaximina, processos para a produção das mesmas e uso das mesmas em preparações medicinais
BRPI0407149A BRPI0407149A8 (pt) 2003-11-07 2004-11-04 formas polimórficas de rifaximin, processos para sua produção e seu uso em preparações medicinais

Family Applications After (1)

Application Number Title Priority Date Filing Date
BRPI0407149A BRPI0407149A8 (pt) 2003-11-07 2004-11-04 formas polimórficas de rifaximin, processos para sua produção e seu uso em preparações medicinais

Country Status (37)

Country Link
US (5) US7045620B2 (pt)
EP (6) EP1676847B1 (pt)
JP (5) JP2005139161A (pt)
KR (4) KR20050043589A (pt)
CN (4) CN1613858A (pt)
AR (3) AR043547A1 (pt)
AT (3) ATE361927T1 (pt)
AU (2) AU2004200964A1 (pt)
BR (2) BRPI0402382A (pt)
CA (2) CA2460384A1 (pt)
CL (1) CL2004000498A1 (pt)
CO (1) CO5560083A1 (pt)
CY (3) CY1108017T1 (pt)
DE (4) DE602004006367C5 (pt)
DK (3) DK1676847T3 (pt)
ES (3) ES2244364T3 (pt)
HR (2) HRP20040265A2 (pt)
IL (2) IL160798A0 (pt)
IT (1) ITMI20032144A1 (pt)
JO (1) JO2470B1 (pt)
MA (1) MA27069A1 (pt)
MD (1) MD3653G8 (pt)
ME (1) ME00424B (pt)
MX (2) MXPA04002353A (pt)
NO (1) NO334950B1 (pt)
NZ (1) NZ531622A (pt)
PL (3) PL1676847T3 (pt)
PT (3) PT1557421E (pt)
RS (4) RS54571B1 (pt)
RU (1) RU2270200C2 (pt)
SI (3) SI1557421T1 (pt)
TN (2) TNSN04044A1 (pt)
TW (1) TWI285107B (pt)
UA (1) UA86384C2 (pt)
WO (1) WO2005044823A2 (pt)
YU (1) YU24804A (pt)
ZA (1) ZA200401948B (pt)

Families Citing this family (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6861053B1 (en) 1999-08-11 2005-03-01 Cedars-Sinai Medical Center Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth
US7048906B2 (en) * 1995-05-17 2006-05-23 Cedars-Sinai Medical Center Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions
US7902206B2 (en) * 2003-11-07 2011-03-08 Alfa Wassermann, S.P.A. Polymorphic forms α, β and γ of rifaximin
US7923553B2 (en) * 2003-11-07 2011-04-12 Alfa Wassermann, S.P.A. Processes for the production of polymorphic forms of rifaximin
US7906542B2 (en) * 2004-11-04 2011-03-15 Alfa Wassermann, S.P.A. Pharmaceutical compositions comprising polymorphic forms α, β, and γ of rifaximin
ITMI20032144A1 (it) 2003-11-07 2005-05-08 Alfa Wassermann Spa Forme polimorfe di rifaximina, processi per ottenerle e
US20080262024A1 (en) * 2003-11-07 2008-10-23 Giuseppe Claudio Viscomi Rifaximin compositions and method of use
PT1698630E (pt) * 2005-03-03 2014-09-15 Alfa Wassermann Spa Novas formas polimorfas de rifaximina, processos para a sua produção e a sua utilização nas preparações medicinais
ITBO20050123A1 (it) 2005-03-07 2005-06-06 Alfa Wassermann Spa Formulazioni farmaceutiche gastroresistenti contenenti rifaximina
MX2009001342A (es) 2006-08-02 2009-08-31 Salix Pharmaceuticals Inc Composiciones y metodos para el tratamiento de proctosigmoiditis por radiacion.
ITMI20061692A1 (it) * 2006-09-05 2008-03-06 Alfa Wassermann Spa Uso di polioli per ottenere forme polimorfe stabili di rifaximina
EP2069363B1 (en) * 2006-09-22 2013-03-20 Cipla Ltd. Rifaximin in an amorphous form
US20080161337A1 (en) * 2007-01-03 2008-07-03 Leonard Weinstock Use of Rifaximin for the Treatment of Chronic Prostatitis
US20080159987A1 (en) * 2007-01-03 2008-07-03 Leonard Weinstock Use of Rifaximin for the Treatment of Restless Legs Syndrome
ITMI20071241A1 (it) * 2007-06-20 2008-12-21 Solmag S P A Processo per la preparazione di rifaximina amorfa e rifaximina amorfa cosi' ottenuta
AU2016203925B2 (en) * 2007-07-06 2016-10-20 Lupin Limited Pharmaceutical compositions of rifaximin
JP5755878B2 (ja) * 2007-07-06 2015-07-29 ルパン リミテッドＬｕｐｉｎ Ｌｉｍｉｔｅｄ リファキシミンの薬剤組成物
ES2798253T3 (es) * 2007-07-06 2020-12-10 Lupin Ltd Composiciones farmacéuticas de rifaximina
US7709634B2 (en) * 2007-09-20 2010-05-04 Apotex Pharmachem Inc. Amorphous form of rifaximin and processes for its preparation
US8486956B2 (en) * 2008-02-25 2013-07-16 Salix Pharmaceuticals, Ltd Forms of rifaximin and uses thereof
US8067429B2 (en) * 2008-02-25 2011-11-29 Salix Pharmaceuticals, Ltd. Forms of rifaximin and uses thereof
PT2252148T (pt) * 2008-02-26 2020-01-23 Salix Pharmaceuticals Ltd Métodos de tratamento da síndrome do intestino irritável
US11779571B2 (en) * 2008-02-26 2023-10-10 Salix Pharmaceuticals, Inc. Methods for treating irritable bowel syndrome (IBS)
HRP20140939T1 (hr) 2008-05-07 2014-11-21 Salix Pharmaceuticals, Ltd. Davanje preparata za äśišä†enje crijeva i antibiotika za lijeäśenje bolesti crijeva
AU2009297562B2 (en) 2008-09-26 2015-04-23 Alfasigma S.P.A. Agent for preventing and/or treating functional gastrointestinal disorder
US20100317681A1 (en) * 2009-06-15 2010-12-16 Salix Pharmaceuticals, Ltd. Modulation of systemic exposure to rifaximin
US12285414B2 (en) 2008-10-02 2025-04-29 Salix Pharmaceuticals, Inc. Methods of treating hepatic encephalopathy
US20110035232A1 (en) 2008-10-02 2011-02-10 Salix Pharmaceuticals, Ltd. Methods of treating hepatic encephalopathy
US7928115B2 (en) 2008-10-02 2011-04-19 Salix Pharmaceuticals, Ltd. Methods of treating travelers diarrhea and hepatic encephalopathy
BRPI0920465A2 (pt) 2008-10-02 2018-03-20 Salix Pharmaceuticals, Inc. metodo de tratamento de encefalopatia hepática
US8916193B2 (en) 2008-12-10 2014-12-23 Cipla Limited Rifaximin complexes
IT1397617B1 (it) * 2009-04-20 2013-01-18 Alfa Wassermann Spa Nuovi derivati della rifamicina
KR20190099100A (ko) 2009-06-02 2019-08-23 샐릭스 파마슈티컬스 리미티드 간성 뇌병증의 치료방법
NZ598671A (en) 2009-09-13 2014-02-28 Salix Pharmaceuticals Ltd Methods for treating irritable bowel syndrome (ibs)
RU2012121599A (ru) * 2009-10-27 2013-12-10 Люпин Лимитед Твердая дисперсия рифаксимина
WO2011061748A1 (en) * 2009-11-19 2011-05-26 Strides Arcolab Limited Rifaximin premix
EP2503989A2 (en) 2009-11-23 2012-10-03 Cipla Limited Topical foam composition
US8952159B2 (en) 2009-12-28 2015-02-10 Silvio Massimo Lavagna Method for the production of amorphous rifaximin
AU2011218129A1 (en) 2010-02-18 2012-08-23 Board Of Regents Of The University Of Texas System Methods for treating infection
IT1398550B1 (it) 2010-03-05 2013-03-01 Alfa Wassermann Spa Formulazioni comprendenti rifaximina utili per ottenere un effetto prolungato nel tempo
WO2011153444A1 (en) * 2010-06-03 2011-12-08 Salix Pharmaceuticals, Ltd New forms of rifaximin and uses thereof
CA2802874A1 (en) * 2010-06-16 2011-12-22 Apotex Pharmachem Inc. Polymorphic forms of rifaximin
SMT202000390T1 (it) * 2010-07-12 2020-09-10 Salix Pharmaceuticals Inc Formulazioni di rifaximina e loro usi
WO2012035544A2 (en) 2010-09-13 2012-03-22 Sequent Scientific Ltd. A novel polymorphic form of rifaximin and process for its preparation
IT1403847B1 (it) 2010-09-22 2013-11-08 Alfa Wassermann Spa Composizioni farmaceutiche comprendenti rifaximina e loro uso.
WO2012060675A1 (es) * 2010-11-05 2012-05-10 Interquim, S.A. De C.V. Proceso para la preparación de rifaximina amorfa
WO2012076832A1 (en) * 2010-12-09 2012-06-14 Cipla Limited Suppositories comprising rifaximin
WO2012109605A2 (en) 2011-02-11 2012-08-16 Salix Pharmaceuticals, Ltd. Forms of rifaximin and uses thereof
CA2834829A1 (en) 2011-05-02 2012-11-08 Ranbaxy Laboratories Limited Rifaximin dimethylformamide solvate
WO2012155981A1 (en) 2011-05-19 2012-11-22 Friulchem Spa New process for the synthesis of rifaximin and a new pseudo-crystalline form of rifaximin obtained thereby
ITMI20110890A1 (it) * 2011-05-19 2012-11-20 A M S A Anonima Materie Sint & Affini S P A Polimorfo di rifaximina e processo per la sua preparazione
ITBO20110461A1 (it) 2011-07-29 2013-01-30 Alfa Wassermann Spa Composizioni farmaceutiche comprendenti rifaximina, processi per la loro preparazione e loro uso nel trattamento di infezioni vaginali.
US20130184302A1 (en) * 2011-11-02 2013-07-18 Enoch Bortey Methods for treating irritable bowel syndrome (ibs) and infections
JP2013184902A (ja) * 2012-03-06 2013-09-19 Aska Pharmaceutical Co Ltd リファキシミン含有結晶
US9359374B2 (en) 2012-06-13 2016-06-07 Apotex Pharmachem Inc. Polymorphic forms of rifaximin
ITBO20120368A1 (it) 2012-07-06 2014-01-07 Alfa Wassermann Spa Composizioni comprendenti rifaximina e amminoacidi, cristalli di rifaximina derivanti da tali composizioni e loro uso.
US9849090B2 (en) 2012-12-12 2017-12-26 Sun Pharmaceutical Industries Limited Pharmaceutical compositions of rifaximin
US20160047819A1 (en) 2013-03-15 2016-02-18 Alfa Wassermann S.P.A. Method for diagnosing vaginal infections
US20160038468A1 (en) 2013-03-15 2016-02-11 Alfa Wassermann S.P.A. Rifaximin for use in the treating of vaginal infections
CN105324109A (zh) 2013-04-12 2016-02-10 意大利阿尔法韦士曼制药公司 Nsaid施用和相关的组合物、方法和系统
US9018225B1 (en) 2013-07-26 2015-04-28 Novel Laboratories Rifaximin crystalline forms and methods of preparation thereof
EP2927235B1 (en) 2014-03-31 2017-02-08 Euticals S.P.A. Polymorphic mixture of rifaximin and its use for the preparation of solid formulations
US9765088B2 (en) 2014-04-19 2017-09-19 Granules India Limited Process for the preparation of rifamycin derivatives
CA2947962C (en) 2014-05-04 2024-01-16 Salix Pharmaceuticals, Inc. Ibs microbiota and uses thereof
AU2015260837B2 (en) 2014-05-12 2019-02-28 Alfasigma S.P.A. New solvated crystal form of rifaximin, production, compositions and uses thereof
MX381919B (es) * 2014-06-30 2025-03-13 Salix Pharmaceuticals Inc Métodos para repetir tratamiento de síndrome del intestino irritable (ibs).
CN104083324B (zh) * 2014-07-10 2017-05-10 青岛动保国家工程技术研究中心有限公司 一种利福昔明的兽用悬乳剂及其制备方法和应用
EP2982764A1 (en) 2014-08-05 2016-02-10 ALFA WASSERMANN S.p.A. Identification of vaginal bacteria
CN104274391B (zh) * 2014-10-08 2017-02-01 哈尔滨坤盟医药科技有限公司 一种含利福昔明的药物制剂
WO2017021975A1 (en) * 2015-08-06 2017-02-09 Msn Laboratories Private Limited Process for the preparation of crystalline forms of rifaximin
HUE040253T2 (hu) 2016-03-24 2019-02-28 Sandoz Ag Rifaximin alfa&deltát tartalmazó gyógyászati készítmény
HUE044432T2 (hu) 2016-03-24 2019-10-28 Sandoz Ag Rifaximin alfá-t tartalmazó, hosszan eltartható kompozíció
US9988398B2 (en) * 2016-06-07 2018-06-05 Cadila Healthcare Limited Crystalline form of rifaximin and process for its preparation
CA3038312A1 (en) 2016-09-30 2018-04-05 Salix Pharmaceuticals, Inc. Solid dispersion forms of rifaximin
CN106632396B (zh) * 2017-01-06 2019-01-11 成都樵枫科技发展有限公司 γ晶型利福昔明的制备方法和用途
CA3013161C (en) 2017-04-26 2020-03-24 Sandoz Ag Oral dosage form comprising rifaximin in form beta
RU2020102511A (ru) 2017-06-26 2021-07-27 Биофер С.П.А. Соединения пиридо-имидазо рифамицина в качестве антибактериального средства
US20220062183A1 (en) * 2018-12-19 2022-03-03 Friulchem S.P.A. Process for the manufacture of a tablet of rifaximin and tablet of rifaximin
CA3142214A1 (en) 2019-06-03 2020-12-10 Bausch Health Ireland Limited Use of methylnaltrexone and rifaximin for treatment of increased gut permeability or associated disorders
MX427410B (es) 2019-09-24 2025-10-13 Bausch Health Ireland Ltd Formulaciones liquidas de rifaximina
WO2021191312A1 (en) 2020-03-24 2021-09-30 Bausch Health Ireland Limited Methods of treating covid-19 with rifaximin
WO2021229480A1 (en) * 2020-05-15 2021-11-18 Atra Pharmaceuticals Limited Polymorph of rifaximin, process for the preparation thereof and pharmaceutical composition containing rifaximin
CA3184054A1 (en) 2020-06-26 2021-12-30 Jacob Cole Targeted release rifaximin compositions
US20230398102A1 (en) 2020-10-29 2023-12-14 Bausch Health Ireland Limited Rifaximin liquid formulations for use inthe treatment of sickle cell disease

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4241785A (en) * 1978-07-24 1980-12-30 Peerless Of America, Inc. Heat exchangers and method of making same
IT1154655B (it) * 1980-05-22 1987-01-21 Alfa Farmaceutici Spa Derivati imidazo-rifamicinici metodi per la loro preparazione e loro uso come sostanza ad azione antibatterica
IT1199374B (it) * 1984-05-15 1988-12-30 Alfa Farmaceutici Spa Processo per la preparazione di pirido-imidazo-rifamicine
CA1215976A (en) 1984-05-15 1986-12-30 Vincenzo Cannata New process for the synthesis of imidazo rifamycins
IT1199413B (it) 1984-09-26 1988-12-30 Alfa Farmaceutici Spa Processo per la preparazione di pirido-imidazo-rifamicine
GB8816620D0 (en) * 1988-07-13 1988-08-17 Lepetit Spa Rifapentine hydrohalides
CA2082809C (en) * 1990-06-29 1995-10-17 Marino Nebuloni Pure crystalline form of rifapentine
IL150524A0 (en) * 2000-01-07 2003-02-12 Transform Pharmaceuticals Inc High-throughput formation, identification, and analysis of diverse solid-forms
UA75365C2 (en) * 2000-08-16 2006-04-17 Bristol Myers Squibb Co Epothilone analog polymorph modifications, a method for obtaining thereof (variants), a pharmaceutical composition based thereon
CA2426393C (en) * 2000-10-31 2012-05-29 Ciba Specialty Chemicals Holding Inc. Crystalline forms of venlafaxine hydrochloride
IL156055A0 (en) * 2000-11-30 2003-12-23 Teva Pharma Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms
ITMI20032144A1 (it) * 2003-11-07 2005-05-08 Alfa Wassermann Spa Forme polimorfe di rifaximina, processi per ottenerle e
US20050262269A1 (en) 2004-05-20 2005-11-24 Pike Jimmy D System and method for information handling system PCI express advanced switching
PT1698630E (pt) 2005-03-03 2014-09-15 Alfa Wassermann Spa Novas formas polimorfas de rifaximina, processos para a sua produção e a sua utilização nas preparações medicinais
EP2069363B1 (en) 2006-09-22 2013-03-20 Cipla Ltd. Rifaximin in an amorphous form
WO2008115572A1 (en) 2007-03-21 2008-09-25 Theraquest Biosciences, Inc. Methods and compositions of nsaids
ITMI20071241A1 (it) 2007-06-20 2008-12-21 Solmag S P A Processo per la preparazione di rifaximina amorfa e rifaximina amorfa cosi' ottenuta
ES2798253T3 (es) 2007-07-06 2020-12-10 Lupin Ltd Composiciones farmacéuticas de rifaximina
JP5755878B2 (ja) 2007-07-06 2015-07-29 ルパン リミテッドＬｕｐｉｎ Ｌｉｍｉｔｅｄ リファキシミンの薬剤組成物
US7709634B2 (en) 2007-09-20 2010-05-04 Apotex Pharmachem Inc. Amorphous form of rifaximin and processes for its preparation
WO2009047801A1 (en) 2007-10-10 2009-04-16 Lupin Limited Therapeutic combinations and compositions for the treatment of gastrointestinal disorders
US8067429B2 (en) 2008-02-25 2011-11-29 Salix Pharmaceuticals, Ltd. Forms of rifaximin and uses thereof

Also Published As

Publication number Publication date
US20050272754A1 (en) 2005-12-08
ES2320161T3 (es) 2009-05-19
EP1557421A1 (en) 2005-07-27
CA2538546A1 (en) 2005-05-19
HK1073657A1 (en) 2005-10-14
US20050101598A1 (en) 2005-05-12
EP1557421B1 (en) 2007-05-09
ITMI20032144A1 (it) 2005-05-08
HK1092151A1 (en) 2007-02-02
ES2244364T1 (es) 2005-12-16
BRPI0407149A (pt) 2006-02-07
US7915275B2 (en) 2011-03-29
JP5199576B2 (ja) 2013-05-15
JP2011057698A (ja) 2011-03-24
EP1676848B1 (en) 2009-01-28
NZ531622A (en) 2004-10-29
PT1557421E (pt) 2007-07-31
RU2270200C2 (ru) 2006-02-20
AR081991A2 (es) 2012-10-31
AR043547A1 (es) 2005-08-03
EP1676848A1 (en) 2006-07-05
WO2005044823A2 (en) 2005-05-19
PL1676847T3 (pl) 2009-07-31
RS20060168A (sr) 2008-09-29
DE602004006367D1 (de) 2007-06-21
JP2011046738A (ja) 2011-03-10
JP2007509904A (ja) 2007-04-19
IL160798A0 (en) 2004-08-31
CA2538546C (en) 2011-04-19
DK1676847T3 (da) 2009-05-11
PL1557421T3 (pl) 2007-08-31
MD3653F2 (en) 2008-07-31
KR100883216B1 (ko) 2009-02-13
AU2004287601A1 (en) 2005-05-19
EP2210893A1 (en) 2010-07-28
CA2460384A1 (en) 2005-05-07
CO5560083A1 (es) 2005-09-30
DK1676848T3 (da) 2009-05-11
ATE421965T1 (de) 2009-02-15
DE602004019296D1 (de) 2009-03-19
DE04005541T1 (de) 2005-12-29
CL2004000498A1 (es) 2005-03-11
MA27069A1 (fr) 2004-12-20
CY1108017T1 (el) 2013-09-04
YU24804A (sh) 2006-08-17
ME00424B (me) 2011-10-10
CY1108964T1 (el) 2014-07-02
AR081992A2 (es) 2012-10-31
CN1886408B (zh) 2010-06-09
PL1676848T3 (pl) 2009-07-31
WO2005044823A3 (en) 2005-10-27
KR20050043589A (ko) 2005-05-11
EP1682556A2 (en) 2006-07-26
JP2014177500A (ja) 2014-09-25
RS20150292A1 (sr) 2015-10-30
HRP20060093A2 (en) 2006-05-31
DE602004019298D1 (de) 2009-03-19
PT1676848E (pt) 2009-04-09
IL174271A (en) 2010-12-30
ATE421966T1 (de) 2009-02-15
CN101260114B (zh) 2012-11-28
RU2004108953A (ru) 2005-10-27
PT1676847E (pt) 2009-04-09
US8404704B2 (en) 2013-03-26
US20080132530A1 (en) 2008-06-05
US20110160449A1 (en) 2011-06-30
TWI285107B (en) 2007-08-11
KR20070113327A (ko) 2007-11-28
RS54569B1 (sr) 2016-06-30
CY1108909T1 (el) 2014-07-02
RS54571B1 (sr) 2016-06-30
AU2004287601B8 (en) 2009-03-05
RS20150291A1 (sr) 2015-10-30
EP2208730A1 (en) 2010-07-21
ES2320160T3 (es) 2009-05-19
HRP20040265A2 (en) 2004-12-31
ZA200401948B (en) 2004-04-29
KR100855084B1 (ko) 2008-08-29
CN1886408A (zh) 2006-12-27
KR100867751B1 (ko) 2008-11-10
AU2004200964A1 (en) 2005-05-26
KR20060110737A (ko) 2006-10-25
DE602004006367C5 (de) 2019-04-04
TW200515913A (en) 2005-05-16
BRPI0407149A8 (pt) 2019-01-15
TNSN06069A1 (en) 2007-10-03
NO20061110L (no) 2006-04-19
US8173801B2 (en) 2012-05-08
DE602004006367T2 (de) 2007-09-06
MXPA04002353A (es) 2005-05-11
SI1557421T1 (sl) 2007-08-31
DK1557421T3 (da) 2007-09-17
AU2004287601B2 (en) 2009-02-26
CN101260114A (zh) 2008-09-10
ES2320160T4 (es) 2011-03-09
HRP20060093B1 (hr) 2015-12-18
JP5635376B2 (ja) 2014-12-03
CN101260115A (zh) 2008-09-10
RS54568B1 (sr) 2016-06-30
EP1676847A1 (en) 2006-07-05
IL174271A0 (en) 2006-08-01
CN1613858A (zh) 2005-05-11
US7045620B2 (en) 2006-05-16
MD3653G8 (ro) 2016-08-31
TNSN04044A1 (en) 2006-06-01
US20120059023A1 (en) 2012-03-08
UA86384C2 (uk) 2009-04-27
JP2005139161A (ja) 2005-06-02
SI1676848T1 (sl) 2009-06-30
MD20060080A (en) 2006-11-30
ATE361927T1 (de) 2007-06-15
MXPA06002644A (es) 2006-06-06
ES2244364T3 (es) 2007-12-01
HK1092150A1 (en) 2007-02-02
JO2470B1 (en) 2009-01-20
CN101260115B (zh) 2011-11-23
SI1676847T1 (sl) 2009-06-30
NO334950B1 (no) 2014-08-04
KR20070113326A (ko) 2007-11-28
EP1676847B1 (en) 2009-01-28

Similar Documents

Publication Publication Date Title
BRPI0407149A (pt) Formas polimórficas de rifaximin, processos para sua produção e seu uso em preparações medicinais
BRPI0608073A2 (pt) formas polimorfas de rifaximina, processos para sua produção e uso das mesmas em composições medicinais
ES2229804T3 (es) Etannolato de azitromicina, procedimiento para su fabricacion y composiciones farmaceuticas que lo contienen.
ES2505615T3 (es) Proceso para fabricar zeolita de tipo MWW de titanio
BRPI0107921B8 (pt) processo para produzir seletivamente monohidrato e hemipentahidrato de ácido 3-piridil-1-hidroxietilideno-1,1-bisfosfônico de sódio
BR0308292A (pt) Processo para aperfeiçoar a pureza e o rendimento da sucralose
BRPI0201437B8 (pt) processos para a preparação de derivados de 9-desoxo-9a-aza-9a-homoeritromicina a 4&#34;-substituídos
BRPI0409905A (pt) forma cristalina aperfeiçoada de sucralose, e método para produzir a mesma
PE20040767A1 (es) Derivado hemisulfato de azido citosina cristalino anhidro
BR0210334A (pt) Processo para a produção de sorbitol por hidrogenação catalìtica de uma solução aquosa de um monossacarìdeo
BR0109508A (pt) Forma ii, cristalina, de cabergolina
BR0315703A (pt) Processos para preparar um sal de perindopril, perindopril t-butilamina, um monohidrato de um sal farmaceuticamente aceitável de perindopril, produtos obtidos e seu uso
BR112019002432A2 (pt) cristalização de glicosídeos de esteviol
BR9815862A (pt) Processo para preparação de zeólito l cristalino
AR046229A1 (es) Procesos para la preparacion de cefalosporina 3-(2-vinilo sustituido) altamente pura
BR0317594A (pt) Processo para a preparação de uma forma &#34;i&#34; de olanzapina polimórfica farmaceuticamente pura, produto resultante e processo para remoção da impureza &#34;s&#34; a partir da forma i polimórfica de olanzapina
EP1623982A4 (en) METHOD FOR PRODUCING DOCETAXEL TRIHYDRATE
PE20010151A1 (es) Nuevas formas cristalinas de un antibiotico macrolido
Mattarei et al. Synthesis of resveratrol sulfates: turning a nightmare into a dream
PE20010287A1 (es) Sal difosfato de un derivado de 4&#34;-sustituido-9-desoxo-9a-aza-9a-homoeritromicina y su composicion farmaceutica
JPS6241230B2 (pt)
RU2806073C1 (ru) Региоселективный энзимный синтез производных кверцетина и мирицетина
BRPI0617561A2 (pt) sal de sódio cristalino antibiótico de cefalosporina
AR047061A1 (es) Sintesis de un polimorfo de clorhidrato hidratado de 4-amino-5-cloro-2-metoxi-n-(1-azabiciclo[3.3.1]non-4-il)benzamida
MY144578A (en) New polymorphous forms of rifaximin, processes for their production and use thereof in the medicinal preparations

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 4A, 5A, 6A, 7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2160 DE 29/05/2012.